
ODTX Stock Forecast & Price Target
ODTX Analyst Ratings
Bulls say
Odyssey Therapeutics is a promising biotech company with a strong preclinical pipeline and a focus on developing treatments for inflammatory and immune diseases. Their production schedule, with a new clinical treatment every 12-18 months, indicates potential for positive financial growth. Early positive results for their lead drug suggest potential for FDA approval and potential for high profits in the future.
Bears say
Odyssey Therapeutics is facing potential risks with their clinical programs and has not yet shown strong efficacy in their drug development. Furthermore, the company is operating at a net loss and is not expected to be profitable for several years. Despite having promising assets in development and a strong cash position, the company's future success will depend on their ability to overcome current challenges and successfully bring their drugs to market.
This aggregate rating is based on analysts' research of Odyssey Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ODTX Analyst Forecast & Price Prediction
Start investing in ODTX
Order type
Buy in
Order amount
Est. shares
0 shares